NASDAQ:RZLT - Nasdaq - US76200L3096 - Common Stock - Currency: USD
4.53
-0.1 (-2.16%)
The current stock price of RZLT is 4.53 USD. In the past month the price decreased by -9.22%. In the past year, price increased by 163.37%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 59 full-time employees. The company went IPO on 2011-12-23. Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
REZOLUTE INC
275 Shoreline Drive, Suite 500
Redwood City CALIFORNIA 94065 US
CEO: Nevan Elam
Employees: 59
Company Website: https://www.rezolutebio.com/
Investor Relations: http://ir.rezolutebio.com
Phone: 16502064507
The current stock price of RZLT is 4.53 USD. The price decreased by -2.16% in the last trading session.
The exchange symbol of REZOLUTE INC is RZLT and it is listed on the Nasdaq exchange.
RZLT stock is listed on the Nasdaq exchange.
16 analysts have analysed RZLT and the average price target is 13.37 USD. This implies a price increase of 195.22% is expected in the next year compared to the current price of 4.53. Check the REZOLUTE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
REZOLUTE INC (RZLT) has a market capitalization of 262.47M USD. This makes RZLT a Micro Cap stock.
REZOLUTE INC (RZLT) currently has 59 employees.
REZOLUTE INC (RZLT) has a support level at 4.51 and a resistance level at 4.84. Check the full technical report for a detailed analysis of RZLT support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RZLT does not pay a dividend.
REZOLUTE INC (RZLT) will report earnings on 2025-05-13, after the market close.
REZOLUTE INC (RZLT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.22).
The outstanding short interest for REZOLUTE INC (RZLT) is 3.07% of its float. Check the ownership tab for more information on the RZLT short interest.
ChartMill assigns a technical rating of 4 / 10 to RZLT. When comparing the yearly performance of all stocks, RZLT is one of the better performing stocks in the market, outperforming 96.43% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to RZLT. RZLT has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months RZLT reported a non-GAAP Earnings per Share(EPS) of -1.22. The EPS decreased by -10.91% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -63.51% | ||
ROE | -71.43% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to RZLT. The Buy consensus is the average rating of analysts ratings from 16 analysts.